Note: [] Address for correspondence: Antonio Villalobo Instituto de
Investigaciones Biomédicas Consejo Superior de Investigaciones
Científicas and Universidad Autónoma de Madrid c/ Arturo Duperier
4 E-28029 Madrid Spain e-mail: antonio.villalobo@iib.uam.es
Abstract: Overexpression and mutations of ErbB receptors are frequently
associated with the high proliferation rate of some tumor cells and the poor
prognosis of patients with different types of cancer. The development of new
potential therapeutic strategies able to curtail the growth of tumor cells is a
highly pursued goal in basic research and in clinicel applications. The
inhibition of the proliferation of tumor cells could be mediated by directly or
indirectly targeting ErbB receptors. Hence, in this minireview three
experimental strategies to attain the arrest of cell proliferation by targeting
ErbB receptors with glycobiological tools are explored. This includes: the
delivery of cytotoxic lectins to the cell interior using ErbB receptors as
carriers, bioengineering tumor cells to modify the normal glycosylation pattern
and function of ErbB receptors, and the use of natural occurring inhibitory
glycoligands for ErbB receptors.